The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis.

IF 1.5 4区医学 Q3 HEMATOLOGY

Transfusion Medicine Pub Date : 2025-05-19 DOI:10.1111/tme.13150

Serhat Çelik, Zeynep Tuğba Güven, Muzaffer Keklik, Ali Ünal, Leylagül Kaynar

{"title":"The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis.","authors":"Serhat Çelik, Zeynep Tuğba Güven, Muzaffer Keklik, Ali Ünal, Leylagül Kaynar","doi":"10.1111/tme.13150","DOIUrl":null,"url":null,"abstract":"Introduction: Therapeutic thrombocytapheresis (TTA) is used to promptly reduce platelet count to prevent thrombohemorrhagic complications that may develop in extreme thrombocytosis. In this study, the efficacy and safety of TTA were investigated in our patients who underwent TTA for extreme thrombocytosis for more than 20 years.Materials and methods: Forty-four patients who underwent TTA due to extreme thrombocytosis between January 2000 and December 2021 in Erciyes University, Faculty of Medicine Therapeutic Apheresis Unit were analysed retrospectively. Extreme thrombocytosis was defined as a platelet count >1000 × 109/L.Results: The median percentage of platelet reduction was 62.2% (28.6%-90.1%). TTA was administered with Spectra Optia in 45.5% (n = 20) and Fresenius in 54.5% (n = 24) of the patients. No statistically significant difference was observed between age, gender, diagnoses, and devices used regarding TTA efficiency. The percentage of platelet reduction was higher in those who had a platelet precount above 1500 × 109/L than those who did not (64.5% ± 9.9% vs. 57.3% ± 12.9%, p = 0.045). No major complications were observed. Mild side effects were observed in five (11.4%) patients.Conclusion: TTA provided prompt, effective, and safe reduction of platelet count in the treatment of extreme thrombocytosis.","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tme.13150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Therapeutic thrombocytapheresis (TTA) is used to promptly reduce platelet count to prevent thrombohemorrhagic complications that may develop in extreme thrombocytosis. In this study, the efficacy and safety of TTA were investigated in our patients who underwent TTA for extreme thrombocytosis for more than 20 years.

Materials and methods: Forty-four patients who underwent TTA due to extreme thrombocytosis between January 2000 and December 2021 in Erciyes University, Faculty of Medicine Therapeutic Apheresis Unit were analysed retrospectively. Extreme thrombocytosis was defined as a platelet count >1000 × 10⁹/L.

Results: The median percentage of platelet reduction was 62.2% (28.6%-90.1%). TTA was administered with Spectra Optia in 45.5% (n = 20) and Fresenius in 54.5% (n = 24) of the patients. No statistically significant difference was observed between age, gender, diagnoses, and devices used regarding TTA efficiency. The percentage of platelet reduction was higher in those who had a platelet precount above 1500 × 10⁹/L than those who did not (64.5% ± 9.9% vs. 57.3% ± 12.9%, p = 0.045). No major complications were observed. Mild side effects were observed in five (11.4%) patients.

Conclusion: TTA provided prompt, effective, and safe reduction of platelet count in the treatment of extreme thrombocytosis.

查看原文本刊更多论文

治疗性血小板清除术治疗重度血小板增多症的疗效和安全性。

导论：治疗性血小板清除术（TTA）用于迅速减少血小板计数，以防止可能在极端血小板增多症中发生的血栓出血性并发症。在这项研究中，我们对20多年来因极端血小板增多而接受TTA治疗的患者进行了TTA的疗效和安全性研究。材料和方法：回顾性分析了2000年1月至2021年12月在埃尔西耶斯大学医学院治疗采血单位因极端血小板增多而接受TTA治疗的44例患者。极端血小板增多定义为血小板计数为1000 × 109/L。结果：血小板减少中位数为62.2%（28.6% ~ 90.1%）。45.5%的患者（n = 20）和54.5%的患者（n = 24）分别使用了Spectra Optia和Fresenius。在年龄、性别、诊断和使用的TTA效率方面，没有观察到统计学上的显著差异。血小板预计数在1500 × 109/L以上的患者血小板减少率高于未计数者（64.5%±9.9% vs. 57.3%±12.9%,p = 0.045）。无重大并发症。5例（11.4%）患者出现轻微副作用。结论：TTA在治疗重度血小板增多症中提供了及时、有效和安全的血小板计数降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine 医学-血液学

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Transfusion Medicine publishes articles on transfusion medicine in its widest context, including blood transfusion practice (blood procurement, pharmaceutical, clinical, scientific, computing and documentary aspects), immunohaematology, immunogenetics, histocompatibility, medico-legal applications, and related molecular biology and biotechnology. In addition to original articles, which may include brief communications and case reports, the journal contains a regular educational section (based on invited reviews and state-of-the-art reports), technical section (including quality assurance and current practice guidelines), leading articles, letters to the editor, occasional historical articles and signed book reviews. Some lectures from Society meetings that are likely to be of general interest to readers of the Journal may be published at the discretion of the Editor and subject to the availability of space in the Journal.